0000785161-20-000009.txt : 20200221 0000785161-20-000009.hdr.sgml : 20200221 20200221163656 ACCESSION NUMBER: 0000785161-20-000009 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20200219 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200221 DATE AS OF CHANGE: 20200221 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Encompass Health Corp CENTRAL INDEX KEY: 0000785161 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOSPITALS [8060] IRS NUMBER: 630860407 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-10315 FILM NUMBER: 20640596 BUSINESS ADDRESS: STREET 1: 9001 LIBERTY PARKWAY CITY: BIRMINGHAM STATE: AL ZIP: 35242 BUSINESS PHONE: 205-967-7116 MAIL ADDRESS: STREET 1: 9001 LIBERTY PARKWAY CITY: BIRMINGHAM STATE: AL ZIP: 35242 FORMER COMPANY: FORMER CONFORMED NAME: HEALTHSOUTH CORP DATE OF NAME CHANGE: 19950113 FORMER COMPANY: FORMER CONFORMED NAME: HEALTHSOUTH REHABILITATION CORP DATE OF NAME CHANGE: 19920703 8-K 1 february2020executivec.htm 8-K Document
false0000785161 0000785161 2020-02-19 2020-02-19


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): February 19, 2020
Encompass Health Corporation
(Exact name of Registrant as specified in its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
001-10315
63-0860407
(Commission File Number)
(IRS Employer Identification No.)
 
 
9001 Liberty Parkway, Birmingham, Alabama 35242
(Address of Principal Executive Offices, Including Zip Code)
(205) 967-7116
(Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.     Emerging growth company   ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.01 per share
EHC
New York Stock Exchange




ITEM 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Compensatory Arrangements of Certain Officers.
At regularly scheduled meetings on February 19-20, 2020, the Board of Directors of Encompass Health Corporation (“Encompass Health”) and its Compensation and Human Capital Committee (the “Committee”) undertook the customary review and approval of annual compensation decisions. The Committee oversees Encompass Health’s compensation and employee benefit objectives, plans and policies and reviews and approves the compensation of executive officers, except that of the Chief Executive Officer which is ultimately approved by the independent members of the Board. The following changes to the 2020 incentive compensation opportunities of certain named executive officers were approved:

•
Mr. Mark J. Tarr, President and Chief Executive Officer
Component
Previous
Newly Approved
Target Annual Cash Incentive Opportunity
115% of base salary
120% of base salary
Target Long-Term Equity Incentive Opportunity
$4,600,000
$4,700,000

•
Ms. Barbara A. Jacobsmeyer, Executive Vice President and President, Inpatient Hospitals
Component
Previous
Newly Approved
Target Annual Cash Incentive Opportunity
80% of base salary
85% of base salary
Target Long-Term Equity Incentive Opportunity
175% of base salary
225% of base salary

•
Mr. Douglas E. Coltharp, Executive Vice President and Chief Financial Officer
Component
Previous
Newly Approved
Target Long-Term Equity Incentive Opportunity
200% of base salary
250% of base salary

No other material changes to Encompass Health’s executive compensation plans and arrangements, which are otherwise described in the section captioned “Executive Compensation” in its Definitive Proxy Statement on Schedule 14A filed on March 21, 2019, were approved at these meetings.






Item 8.01. Other Events.

As previously disclosed, at the time that Encompass Health acquired its home health and hospice business through the purchase of EHHI Holdings, Inc. (“EHHI”) in December 2014, certain sellers of EHHI who were members of EHHI management (the “Management Investors”) contributed a portion of their shares of EHHI common stock, valued at approximately $64 million on the acquisition date, to a subsidiary of Encompass Health (“Holdings”) that was formed in order to complete the acquisition and that is an indirect parent of EHHI, in exchange for approximately 16.7% of the outstanding shares of common stock of Holdings (the “Rollover Shares”). Pursuant to a stockholders agreement entered into among Encompass Health, Holdings and the Management Investors, the Management Investors had the right (but not the obligation) after December 31, 2017 to have their Rollover Shares purchased by Encompass Health for a cash purchase price per share equal to their fair value.

In February 2018 and July 2019, the Management Investors exercised their right to sell Rollover Shares to Encompass Health, with Encompass Health having settled these exercises upon the payment in cash of approximately $65 million and approximately $163 million, respectively.

In January 2020, Encompass Health received exercise notices for additional Rollover Shares, which Encompass Health settled for approximately $162 million in cash in February 2020.  Upon settlement of these exercises, approximately $46 million of the Rollover Shares remain outstanding, of which (i) approximately $45 million are held by HCHB Consulting, Inc. (“HCHB”), an entity in which April Anthony, the chief executive officer of EHHI and an executive officer of Encompass Health, has a material interest, and (ii) approximately $1 million are held by another Management Investor (together with HCHB, the “Subsidiary Shareholders” and, each, a “Subsidiary Shareholder”).

On February 20, 2020, Encompass Health entered into an exchange agreement (each, an “Exchange Agreement”) with each of the Subsidiary Shareholders, pursuant to which they have the right to exchange all of the remaining Rollover Shares held by them for shares of common stock of Encompass Health (the “EHC Shares”). Each of the Exchange Agreements provides that the Subsidiary Shareholder must deliver a written exchange notice (an “Exchange Notice”) to Encompass Health in order to exchange his or her remaining Rollover Shares for EHC Shares. Each Exchange Agreement further provides that the number of EHC Shares to be delivered to the Subsidiary Shareholder is to be determined by dividing the fair value of the Rollover Shares held by the Subsidiary Shareholder on the date of the Exchange Agreement by the last reported sales price of Encompass Health’s common stock on the New York Stock Exchange (the “NYSE”) on the date of delivery of the Exchange Notice.

On February 20, 2020, Encompass Health received an Exchange Notice from each of the Subsidiary Shareholders. Based on the last sales price of the Company’s common stock on the NYSE on February 20, 2020, the Company anticipates delivering an aggregate of approximately 561,000 EHC Shares to the Subsidiary Shareholders, with the settlement of the exchanges expected to occur prior to the end of the first quarter of 2020. The total number of EHC Shares to be issued to the Subsidiary Shareholders pursuant to the Exchange Agreements represents less than 0.6% of the total number of outstanding shares of the Company’s common stock. The Company anticipates issuing the EHC Shares from its treasury shares. The EHC Shares to be issued to the Subsidiary Shareholders are being issued in a transaction exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), and will constitute “restricted securities” within the meaning of Rule 144 under the Securities Act. Following the settlement of the exchange transaction, Holdings and EHHI will be wholly-owned subsidiaries of Encompass Health.

The foregoing description of the terms of the Exchange Agreements is not intended to be complete and is qualified in its entirety by reference to the Exchange Agreement with HCHB, a copy of which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.

Forward-Looking Statements

Statements contained in this Current Report on Form 8-K which are not historical facts, such as those relating to the anticipated settlement of the exchange of Rollover Shares for EHC Shares pursuant to the terms of the Exchange Agreements and the status of Holdings and EHHI following the exchange, are forward-looking statements. In addition, Encompass Health, through its senior management, may from time to time make forward-looking public statements concerning the matters described herein. All such estimates, projections and forward-looking information speak only as of the date hereof, and Encompass Health undertakes no duty to publicly update or revise such forward-looking information, whether as a result of new information, future events, or otherwise. Such forward-looking statements are necessarily estimates based upon current information and involve a number of risks and uncertainties. Actual events or results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such




factors, factors which could cause actual events or results to differ materially from those estimated by Encompass Health include, but are not limited to, Encompass Health’s ability to consummate the exchange of Rollover Shares for EHC Shares on the terms described or at all; and other factors which may be identified from time to time in Encompass Health’s SEC filings and other public announcements, including its Form 10-K for the year ended December 31, 2018 and Forms 10-Q for the quarters ended March 31, 2019, June 30, 2019 and September 30, 2019.


Item 9.01. Financial Statements and Exhibits.

(d)    Exhibits.
Exhibit Number
 
Description
 
104
 
Cover Page Interactive Data File - the cover page iXBRL tags are embedded within the Inline XBRL document





SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

ENCOMPASS HEALTH CORPORATION
By:
/S/ PATRICK DARBY
 
Name:
Patrick Darby
 
Title:
Executive Vice President, General Counsel and Secretary
Dated: February 21, 2020



 EX-10.1 2 ex101exchangeagreement.htm EXHIBIT 10.1 Exhibit

Exhibit 10.1

EXCHANGE AGREEMENT
This Exchange Agreement (this “Agreement”) is entered into as of February 20, 2020, by and between Encompass Health Corporation, a Delaware corporation (the “Company”), HCHB Consulting, Inc., a Delaware corporation (“Shareholder”) and, solely for purposes of Section 1 hereof, Encompass Health Home Health Holdings, Inc., a Delaware corporation (the “Subsidiary”).
RECITALS
A.Shareholder and Company each are a party to that certain Stockholders’ Agreement, dated as of December 31, 2014 by and among the Company, Shareholder, the Subsidiary and certain other Management Investors (the “Stockholders’ Agreement”);
B.The parties hereto have determined that with respect to 46,751 shares of Subsidiary Common Stock (the “Exchanged Subsidiary Shares”), the parties desire to effect an exchange of the Exchanged Subsidiary Shares for common stock of the Company, par value $0.01 per share (the “Company Common Stock”) on the terms and subject to the conditions of this Agreement (such transaction, the “Exchange”);
C.As of the date hereof, the Company and Shareholder agree that the Fair Market Value of the Exchanged Subsidiary Shares, as determined pursuant to the Stockholders’ Agreement, is $45,312,471.73 (the “Exchanged Subsidiary Shares Value”).
D.The Company desires to deliver a number of shares of Company Common Stock as determined under this Agreement (the “Exchanged Company Shares”) to Shareholder in exchange for the Exchanged Subsidiary Shares, on the terms and subject to the conditions of this Agreement; and
E.It is the intention of the parties hereto that the Exchange shall be a transaction satisfying the requirements of section 368(a) of the Internal Revenue Code of 1986, as amended (the “Code”).
AGREEMENT
NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as set forth below. All capitalized terms used but not herein defined shall have the meaning set forth in the Stockholders’ Agreement.


1.Matters Related to the Stockholders’ Agreement
a.    Pursuant to subparagraph (vi) of the definition of “Permitted Transferee” in the Stockholders’ Agreement, the Company hereby approves the Exchange and the transfer of the Exchanged Subsidiary Shares to the Company, and the Subsidiary hereby acknowledges and agrees that the Company is a “Permitted Transferee” as defined in the Stockholders’ Agreement.
b.    The Subsidiary hereby waives any requirement that the Shareholder deliver to the Subsidiary the opinion described in Section 3.02 of the Stockholders’ Agreement in connection with the Exchange.
c.    Pursuant to Section 3.01 of the Stockholders’ Agreement, the Company agrees to take the Exchanged Subsidiary Shares subject to, and to comply with, all of the provisions of the Stockholders’ Agreement applicable thereto, and shall cause a copy of this Agreement to be filed with the Secretary of the Subsidiary.
2.    Mechanics of Exchange
a.    No earlier than February 11, 2020 and no later than the end of the day on March 12, 2020 (such period, the “Exchange Notice Period”), Shareholder may deliver a notice (the “Exchange Notice”) in writing to the Company of Shareholder’s intention to exchange all, but not less than all, of the Exchanged Subsidiary Shares for the number of Exchanged Company Shares determined pursuant to this Section 2. If no Exchange Notice is delivered by the Shareholder during the Exchange Notice Period, this Agreement shall terminate and be of no further force or effect with respect to the Exchanged Subsidiary Shares.
b.    No later than five (5) business days following receipt of the Exchange Notice, the Company shall deliver to Shareholder a calculation setting forth the number of Exchanged Company Shares to be delivered in the Exchange. The number of shares of Exchanged Company Shares to be delivered in the Exchange shall be determined by dividing the Exchanged Subsidiary Shares Value by an amount per share (rounded to two decimal places) equal to the last reported sales price of a share of the Common Stock on the composite tape of the New York Stock Exchange (the “NYSE”) on the date on which the Exchange Notice was delivered (the “Exchanged Company Shares Value”). If the Exchange Notice is delivered after 5 p.m. central time or on a day on which the NYSE was not open for trading, the Exchanged Company Shares Value will be determined using the last reported sales price for the Company Common Stock on the next trading day following the date on which the Exchange Notice was delivered.
c.    No later than five (5) days following the delivery by the Company of its determination of the Exchanged Company Shares Value, provided that any conditions precedent and closing deliveries have been satisfied or provided, as applicable, Shareholder shall transfer to the Company all of Shareholder’s right, title and interest in and to the Exchanged Subsidiary Shares and in consideration of the assignment by Shareholder of the


Exchanged Subsidiary Shares, the Company shall deliver to Shareholder the Exchanged Company Shares, rounded down to the nearest whole number of shares, and cash in an amount equal to the Exchanged Company Share Value multiplied by the number of fractional shares of Company Common Stock that otherwise would have been issued in the Exchange (the consummation of such transfer and delivery, the “Closing”). The Company and the Shareholder agree that payment of cash in lieu of fractional shares of Company Common Stock is solely for the purpose of avoiding the expense and inconvenience to the Company of issuing fractional shares and does not represent separately bargained-for consideration.
3.    Representations and Warranties of the Company. The Company hereby represents and warrants to Shareholder as follows:
a.    The execution and delivery by the Company of this Agreement, and the performance of its obligations hereunder, have been duly and validly authorized by all necessary actions of the Company. This Agreement has been duly and validly executed and delivered by the Company and constitutes the legal, valid and binding obligations of the Company, enforceable against the Company, in accordance with its terms, except to the extent such enforceability (i) may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws relating to creditors’ rights generally and (ii) is subject to general principles of equity.
b.    The consummation of the transactions contemplated by this Agreement and the execution, delivery and performance of the terms and provisions of this Agreement by the Company will not (i) contravene, result in any breach of, or constitute a default under, any material agreement or instrument to which the Company is a party, (ii) conflict with or result in a breach of any of the terms, conditions or provisions of any order of any court, arbitrator or governmental authority applicable to the Company, or (iii) violate any provision of any statute or other rule or regulation of any governmental authority applicable to the Company.
c.    The Exchanged Company Shares sold and delivered in accordance with the terms and for the consideration set forth in this Agreement, will be validly issued, fully paid and nonassessable.
4.    Representations and Warranties of Shareholder. Shareholder represents and warrants to the Company as follows:
a.    Shareholder is an entity duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization with the requisite power and authority to enter into and to consummate the transactions contemplated by this Agreement, to effect the Exchange, and otherwise to carry out its obligations hereunder and thereunder.
b.    The execution and delivery by Shareholder of this Agreement, and the performance of its obligations hereunder, have been duly and validly authorized by all necessary actions of Shareholder. This Agreement has been duly and validly executed and delivered by Shareholder and constitutes the legal, valid and binding obligations of


Shareholder, enforceable against Shareholder, in accordance with its terms, except to the extent such enforceability (i) may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws relating to creditors’ rights generally and (ii) is subject to general principles of equity.
c.    The consummation of the transactions contemplated by this Agreement and the execution, delivery and performance of the terms and provisions of this Agreement by Shareholder will not (i) contravene, result in any breach of, or constitute a default under, any material agreement or instrument to which Shareholder is a party, (ii) conflict with or result in a breach of any of the terms, conditions or provisions of any order of any court, arbitrator or governmental authority applicable to Shareholder, or (iii) violate any provision of any statute or other rule or regulation of any governmental authority applicable to Shareholder.
d.    Shareholder is the sole and exclusive legal and beneficial owner of the Exchanged Subsidiary Shares, free and clear of all prior claims and any lien, mortgage, security interest, pledge, restriction on transferability, and there are no (i) voting trusts, stockholder or other agreements, proxies or other understandings in effect (except for the Stockholders’ Agreement) with respect to the voting or transfer of any of the Exchanged Subsidiary Shares or (ii) judgments, orders, injunctions, decrees, stipulations or awards (whether rendered by a court, administrative agency, arbitral body or governmental authority) against Shareholder with respect to any of the Exchanged Subsidiary Shares.
e.    Shareholder is acquiring all of the Exchanged Company Shares for Shareholder’s own account, for investment purposes, and not with a view to or for sale in connection with any distribution of the Exchanged Company Shares. Shareholder specifically represents that the entire legal and beneficial interest in the Exchanged Company Shares is being acquired for, and will be held for, Shareholder’s account only and not for the account of, or otherwise on behalf of, any other person.
f.    Shareholder has had a full opportunity to ask questions through its representatives and to receive answers concerning the terms and conditions of the transactions contemplated by this Agreement and has had full access to the Company’s officers and such other information concerning the Company as he has requested.
g.    Shareholder is an accredited investor as defined in Rule 501(a) of Regulation D promulgated under the Securities Act of 1933, as amended (the “Act”).
h.    By reason of Shareholder’s business or financial experience, Shareholder has the capacity to protect Shareholder’s own interests in connection with the transactions contemplated by this Agreement, and Shareholder can bear the risk of losing Shareholder’s entire investment in the Company.
i.    The Shareholder is a “United States person” within the meaning of Section 7701(a)(30) of the Code and the Treasury Regulations thereunder.


j.    Shareholder has relied only upon its own tax advisor and legal counsel with respect to the federal, state, local, foreign and other tax consequences arising from such Shareholder’s acquisition, ownership, and potential future disposition of the Exchanged Company Shares in the Exchange, and not on the Company or the Subsidiary, or either of their respective advisors. Shareholder acknowledges that neither the Company, the Subsidiary, nor their respective advisors has made any representations regarding the federal, state, local, foreign or other tax consequences of consummating the transactions contemplated by this Agreement.
5.    Legends. Shareholder acknowledges that (i) the offer and sale of the Exchanged Company Shares in the Exchange have not been registered under the Act, or registered or qualified under the securities laws of any state, and instead have been offered and are being sold pursuant to one or more exemptions from registration or qualification, and (ii) the Exchanged Company Shares are “restricted securities” within the meaning of Rule 144 under the Act, and Shareholder may not sell or otherwise transfer the Exchanged Company Shares unless they are subsequently registered under the Act and registered or qualified under applicable state securities laws, or unless an exemption is available which permits the sale or other transfer without such registration and qualification. Shareholder acknowledges that the Company has no obligation to register the Exchanged Company Shares or to ensure that any sale or other transfer of the Exchanged Company Shares by Shareholder complies with the requirements of any exemption from such registration or qualification. Shareholder understands and agrees that all certificates, if any, evidencing the Exchanged Company Shares to be issued to Shareholder shall bear substantially the following legend:
THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD OR OTHERWISE TRANSFERRED OR DISPOSED OF UNLESS THEY HAVE BEEN REGISTERED UNDER SUCH ACT AND ALL SUCH APPLICABLE LAWS OR AN EXEMPTION FROM REGISTRATION IS AVAILABLE.
6.    Transaction Upon Execution.     The following deliveries and transactions shall take place at the Closing:
a.    The Company shall deliver or cause to be delivered to Shareholder:
i.    the Exchanged Company Shares, recorded in book-entry form or certificated form, as determined by the Company in its sole discretion, in the name of Shareholder with the Company’s transfer agent, Computershare, Inc.;
ii.    cash (by check, money order or wire transfer) in lieu of the issuance of any Fractional Shares, in such amount as provided for in Section 2(c) of this Agreement; and


iii.    such further instruments and documents as may be necessary or appropriate to consummate the transactions contemplated herein, all duly executed by the Company.
b.    Shareholder shall deliver to the Company:
i.    stock certificates of Subsidiary evidencing the Exchanged Subsidiary Shares, together with appropriate stock powers executed in blank;  
ii.    a certificate substantially in the form set forth in, and satisfying the requirements of, Treasury regulation section 1.1445-2(b)(2), in form and substance reasonably satisfactory to the Company, and an executed IRS Form W-9 or applicable successor form;
iii.    a copy of the notice provided to the Subsidiary as required under Section 3.01 of the Stockholders’ Agreement; and
iv.    such further instruments and documents as may be reasonably necessary or appropriate to consummate the transactions contemplated herein, all duly executed by Shareholder.
7.    General Provisions.
a.    Successors and Assigns. This Agreement will be binding on the parties and their respective legal representatives, successors and permitted assigns.
b.    No Third Party Beneficiaries. Except as may be expressly provided in this Agreement, there shall be no third party beneficiaries.
c.    Governing Law; Jurisdiction. This Agreement shall be governed by and construed in accordance with the internal laws of the State of Delaware, without regard to conflict of law principles that would result in the application of any law other than the law of the State of Delaware. The parties (i) hereby irrevocably and unconditionally submit to the jurisdiction of the state and federal courts located in the State of Delaware for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement (“Covered Matters”), (ii) agree not to commence any suit, action or other proceeding arising out of or based upon any Covered Matters except in the state or federal courts located in the State of Delaware, and (iii) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that a party is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter of any Covered Matter may not be enforced in or by such court.


d.    Further Assurances. The Company and Shareholder shall, at any time and from time to time following the date hereof promptly execute and deliver, or cause to be executed and delivered all such further instruments and take all such further actions as may be reasonably necessary or appropriate to confirm or carry out the purposes and intent of this Agreement.
e.    Entire Agreement. This Agreement constitutes the full and entire understanding and agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled.
f.    Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute a single agreement.
g.    Amendment. This Agreement may be amended or modified only by a written instrument executed by all of the parties to this Agreement.
h.    Counterparts; Delivery. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes
i.    Withholding. The Company shall be entitled to deduct and withhold from any transfers to be made under this Agreement any amounts required to be deducted or withheld under applicable federal, state, local or foreign law; provided, that Company does not expect to be required to withhold any amounts from any transfers made under this Agreement provided that Shareholder complies with Section 6(b)(ii) hereof. Any amount so deducted and withheld, when paid over to the appropriate governmental authority, shall be treated as having been paid to the person in respect of which such deduction or withholding was made for all purposes of this Agreement.
j.    Notices. All notices, requests, demands, claims and other communications required or permitted hereunder will be in writing and will be sent by personal delivery, nationally recognized overnight courier or facsimile or, provided that one of the foregoing methods of delivery is also used, by e-mail (as a PDF). Any notice, request, demand, claim, or other communication required or permitted hereunder will be deemed duly given, as applicable, (1) upon personal delivery, (2) one (1) Business Day following the date sent when sent by courier delivery or (3) upon confirmation of receipt when sent by facsimile or e-mail (as a PDF), addressed as follows:


If to the Company, to:
Encompass Health Corporation
9001 Liberty Parkway
Birmingham, Alabama 35242
Telephone number: (205) 967-7116
Facsimile number: (205) 262-3948
Attention: General Counsel
If to Shareholder, to: 
 
HCHB Consulting, Inc.
c/o April Anthony
3616 Euclid Avenue
Dallas, Texas 75205





[Signature Page Follows]


IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the day and year first above written.
COMPANY:
ENCOMPASS HEALTH CORPORATION


By:    /s/ Patrick Darby            
Name: Patrick Darby
Title:
Executive Vice President, General Counsel and Secretary


SHAREHOLDER:

HCHB CONSULTING, INC.

By: /s/ April Anthony            
Name: April Anthony
Title: President

SUBSIDIARY
(Solely for purposes of Section 1 hereof):

ENCOMPASS HEALTH HOME HEALTH HOLDINGS, INC.


By:    /s/ Patrick Darby        
Name: Patrick Darby
Title:
Vice President and Secretary




 EX-101.SCH 3 ehc-20200219.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001000 - Document - Document and Entity Information Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 ehc-20200219_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 ehc-20200219_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 ehc-20200219_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover page. Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Pre-commencement Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key EX-101.PRE 7 ehc-20200219_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ZIP 9 0000785161-20-000009-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000785161-20-000009-xbrl.zip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february2020executivec_htm.xml IDEA: XBRL DOCUMENT 0000785161 2020-02-19 2020-02-19 false 0000785161 8-K 2020-02-19 Encompass Health Corporation DE 001-10315 63-0860407 9001 Liberty Parkway Birmingham AL 35242 205 967-7116 false false false false false Common Stock, par value $0.01 per share EHC NYSE XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 R1.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Document and Entity Information Document and Entity Information
Feb. 19, 2020
Cover page.  
Document Type 8-K
Document Period End Date Feb. 19, 2020
Entity Registrant Name Encompass Health Corporation
Entity Incorporation, State or Country Code DE
Entity File Number 001-10315
Entity Tax Identification Number 63-0860407
Entity Address, Address Line One 9001 Liberty Parkway
Entity Address, City or Town Birmingham
Entity Address, State or Province AL
Entity Address, Postal Zip Code 35242
City Area Code 205
Local Phone Number 967-7116
Written Communications false
Soliciting Material false
Pre-commencement Issuer Tender Offer false
Pre-commencement Tender Offer false
Entity Emerging Growth Company false
Title of 12(b) Security Common Stock, par value $0.01 per share
Trading Symbol EHC
Security Exchange Name NYSE
Amendment Flag false
Entity Central Index Key 0000785161
XML 13 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} EXCEL 14 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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etaLinks.json IDEA: XBRL DOCUMENT { "instance": { "february2020executivec.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "ehc-20200219_cal.xml" ] }, "definitionLink": { "local": [ "ehc-20200219_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "february2020executivec.htm" ] }, "labelLink": { "local": [ "ehc-20200219_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "ehc-20200219_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "ehc-20200219.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ehc", "nsuri": "http://www.encompasshealth.com/20200219", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "february2020executivec.htm", "contextRef": "D2020Q1Feb19-2020throughFeb19-2020", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Document and Entity Information Document and Entity Information", "role": "http://www.encompasshealth.com/role/DocumentAndEntityInformationDocumentAndEntityInformation", "shortName": "Document and Entity Information Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "february2020executivec.htm", "contextRef": "D2020Q1Feb19-2020throughFeb19-2020", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.encompasshealth.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.encompasshealth.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.encompasshealth.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.encompasshealth.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.encompasshealth.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.encompasshealth.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.encompasshealth.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.encompasshealth.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.encompasshealth.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.encompasshealth.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.encompasshealth.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.encompasshealth.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.encompasshealth.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.encompasshealth.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.encompasshealth.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.encompasshealth.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.encompasshealth.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.encompasshealth.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.encompasshealth.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.encompasshealth.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.encompasshealth.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.encompasshealth.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 16 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 1 95 1 false 0 0 false 0 false false R1.htm 0001000 - Document - Document and Entity Information Document and Entity Information Sheet http://www.encompasshealth.com/role/DocumentAndEntityInformationDocumentAndEntityInformation Document and Entity Information Document and Entity Information Cover 1 false false All Reports Book All Reports february2020executivec.htm ehc-20200219.xsd ehc-20200219_cal.xml ehc-20200219_def.xml ehc-20200219_lab.xml ehc-20200219_pre.xml ex101exchangeagreement.htm http://xbrl.sec.gov/dei/2019-01-31 true true